BCL2 and acute myeloid leukemia: This is similar to the effects of the Bcl-2 inhibitor venetoclax, which has limited single-agent clinical activity [35], but potently enhances the clinical efficacy of demethylating agents in AML [36], and was recently approved by the United States Food and Drug Administration for use in these combination regimens.